Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Short-Term stronger blood thinner may cut heart risks in AF patients

NCT ID NCT04981041

Disease control Sponsor: Ludwig-Maximilians - University of Munich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether giving a more powerful antiplatelet drug (prasugrel or ticagrelor) for one month after a heart attack, along with a standard blood thinner, could reduce heart attacks, strokes, and deaths in people with atrial fibrillation. The 602 participants were then switched to a milder drug. The goal was to find a balance between preventing clots and avoiding dangerous bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prasugrel or Ticagrelor (potent antiplatelet drugs)
What this could lead to
If it works, this could offer a safer way to prevent heart attacks and strokes in people with atrial fibrillation after a heart attack, using a short course of stronger medication.
What could go wrong
This is a completed Phase 4 trial with 602 participants, so results are available but may not apply to everyone. The stronger drugs can increase bleeding risk, and the benefit may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

602 people

The number who actually took part.

Started

Dec 2021

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent * Age ≥ 18 years * Atrial fibrillation requiring oral anticoagulation * STEMI or NSTEMI (biomarker positive acute coronary syndrome) and successful completion of PCI (randomization will take place within 24h after successful PCI) Exclusion Criteria: * Chronic renal insufficiency with glomerular filtration rate \< 15 ml/min/1.73m2 * History of ischaemic stroke or transient ischaemic attack (both contraindications for Prasugrel) and history of intracranial bleeding (contraindication for Ticagrelor) * Contraindication for Clopidogrel or Aspirin * Contraindication for P2Y12-inhibitor * Severe chronic liver disease (Child-Pugh C) * Indication for oral anticoagulation with Vitamin K antagonists * Moderate to severe mitral stenosis or mechanical heart valve * Any bleeding BARC type ≥ 2 within the last 4 weeks before index procedure * Pregnancy or lactation * Inability to cooperate with the protocol requirements * Life expectancy \< 6 months * Participation in another investigational drug study * Previous enrolment in this study * For women of childbearing potential no negative pregnancy test and no agree to use a reliable method of birth control during the study * Previous treatment with GP IIb/IIIa inhibitors within the last 12 hours * A known genetic disorder involved in the metabolism of the study medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Atrial fibrillation

Contacts and locations

Locations

  • Barmherzige Brüder, Klinikum St. Elisabeth Straubing GmbH, II. Medizinische Klinik Innere Medizin, Kardiologie, Intensivmedizin, Pneumologie, Nephrologie und Angiologie

    Straubing, 94315, Germany

  • Campus Benjamin Franklin

    Berlin, Germany

  • Campus Virchow-Klinikum

    Berlin, Germany

  • Deutsches Herzzentrum München

    Munich, Bavaria, 80636, Germany

  • Evangelisches Krankenhaus Hagen-Haspe gGmbH, Klinik für Kardiologie und Rhythmologie

    Hagen, 58135, Germany

  • HBK Hegau-Bodensee Klinikum Singen

    Singen, Germany

  • Helios Amper-Klinikum Dachau Kardiologie und Pneumologie Krankenhausstraße 15 85221 Dachau

    Dachau, Germany

  • Herzzentrum Dresden GmbH Universitätsklinik an der Technischen Universität Dresden, Klinik für Innere Medizin und Kardiologie

    Dresden, 01307, Germany

  • Herzzentrum Leipzig, Universitätsklinik für Kardiologie

    Leipzig, 04289, Germany

  • Kerckhoff-Klinik GmbH, Herzzentrum

    Bad Nauheim, 61231, Germany

  • Klinikum Bielefeld gem. GmbH Universitätsklinikum für Kardiologie und Internistische Intensivmedizin

    Bielefeld, 33604, Germany

  • Klinikum Coburg, Kardiologie-Angiologie Ketschendorfer Str. 33 96450 Coburg

    Coburg, Germany

  • Klinikum Friedrichshafen, Medizin Campus Bodensee Klinik für Kardiologie, Angiologie, Pneumologie und internistische Intensivmedizin Röntgenstraße 2 88048 Friedrichshafen

    Friedrichshafen, Germany

  • Klinikum Ingolstadt Medizinische Klinik I Krumenauerstraße 25 85049 Ingolstadt

    Ingolstadt, Germany

  • Klinikum Konstanz Medizinische Klinik, Studienzentrum Mainaustr. 35 78464 Konstanz

    Konstanz, Germany

  • Klinikum Landkreis Erding

    Erding, Germany

  • Klinikum Nürnberg Süd, Klinik für Innere Medizin 8, Schwerpunkt Kardiologie

    Nuremberg, 90471, Germany

  • LMU-Klinikum Campus Grosshadern

    Munich, 81377, Germany

  • LMU-Klinikum Campus Innenstadt

    Munich, Germany

  • Medizinische Hochschule Hannover,Zentrum für Innere Medizin

    Hanover, 30625, Germany

  • Medizinische Universität Innsbruck Universitätsklinik für Innere Medizin III - Kardiologie und Angiologie Anichstraße 35 6020 Innsbruck, Austria

    Innsbruck, Austria

  • München Klinik Bogenhausen, Klinik für Kardiologie und Internistische Intensivmedizin

    München, Germany

  • Sana Klinikum Lichtenberg Klinik für Innere Medizin II: Kardiologie Fanningerstraße 32 10365 Berlin

    Berlin, Germany

  • St. Vincenz Krankenhaus Paderborn Medizinische Klinik II Kardiologie und internistische Intensivmedizin Am Busdorf 2 33098 Paderborn

    Paderborn, Germany

  • Universitäres Herzzentrum Universitätsklinikum Frankfurt am Main Goethe-Universität

    Frankfurt am Main, 60590, Germany

  • Universitätsklinikum Bonn (AöR) Medizinische Klinik und Poliklinik II - Herzzentrum Venusberg-Campus 1 53127 Bonn

    Bonn, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Universitätsklinikum Freiburg, Universitäts-Herzzentrum Klinik für Kardiologie & Angiologie, Campus Bad Krozingen

    Bad Krozingen, 79189, Germany

  • Universitätsklinikum Freiburg, Universitäts-Herzzentrum Klinik für Kardiologie & Angiologie, Campus Freiburg

    Freiburg im Breisgau, 79106, Germany

  • Universitätsklinikum Heidelberg, Klinik für Kardiologie, Angiologie, Pneumologie

    Heidelberg, 69120, Germany

  • Universitätsklinikum Mannheim Medizinische Klinik Kardiologie, Angiologie, Hämostaseologie, Internistische Intensivmedizin Theodor-Kutzer-Ufer 1-3 68167 Mannheim

    Mannheim, Germany

  • Universitätsklinikum Schleswig-Holstein (UKSHL) Campus Lübeck Medizinische Klinik II (Kardiologie, Angiologie, Intensivmedizin) Universitäres Herzzentrum Lübeck Ratzeburger Allee 160 23538 Lübeck, Deutschland

    Lübeck, Germany

  • Universitätsklinikum Schleswig-Holstein -Campus Kiel- Klinik für Innere Medizin III mit den Schwerpunkten Kardiologie, Angiologie und internistische Intensivmedizin

    Kiel, 25105, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Universitätsmedizin Mainz, Zentrum für Kardiologie - Kardiologie I

    Mainz, 55131, Germany

  • Universitätsmedizin Rostock, Zentrum Innere Medizin, Abteilung Kardiologie

    Rostock, 18057, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.